Melissa A. Starovasnik Net Worth

The estimated Net Worth of Melissa A. Starovasnik is at least $549 mil dollars as of 9 February 2023. Melissa Starovasnik owns over 1,732 units of Twist Bioscience Corp stock worth over $503,042 and over the last 3 years Melissa sold TWST stock worth over $45,829.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Melissa Starovasnik TWST stock SEC Form 4 insiders trading

Melissa has made over 1 trades of the Twist Bioscience Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently Melissa sold 1,732 units of TWST stock worth $45,829 on 9 February 2023.

The largest trade Melissa's ever made was selling 1,732 units of Twist Bioscience Corp stock on 9 February 2023 worth over $45,829. On average, Melissa trades about 346 units every 0 days since 2021. As of 9 February 2023 Melissa still owns at least 11,340 units of Twist Bioscience Corp stock.

You can see the complete history of Melissa Starovasnik stock trades at the bottom of the page.

What's Melissa Starovasnik's mailing address?

Melissa's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Twist Bioscience Corp

Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell y Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.

What does Twist Bioscience Corp do?

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .

Complete history of Melissa Starovasnik stock trades at Twist Bioscience Corp

Twist Bioscience Corp executives and stock owners

Twist Bioscience Corp executives and other stock owners filed with the SEC include:

• Emily Leproust,
  Chairman of the Board, President, Chief Executive Officer
• James Thorburn,
  Chief Financial Officer
• Patrick Finn,
  Chief Commercial Officer
• Dr. Emily Marine Leproust Ph.D.,
  Co-Founder, Chairman, Pres & CEO
• Patrick Weiss,
  Chief Operating Officer
• James M. Thorburn,
  Chief Financial Officer
• Dr. Patrick John Finn Ph.D.,
  Chief Commercial Officer
• Mark Daniels,
  Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary
• Dr. William Charles Banyai Ph.D.,
  Sr. VP of Advanced Devel., GM of Data Storage & Director
• Jan Johannessen,
  Independent Director
• Nelson Chan,
  Independent Director
• Robert Ragusa,
  Independent Director
• Keith Crandell,
  Independent Director
• Robert Chess,
  Lead Independent Director
• Xiaoying Mai,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• William Banyai,
  Director
• Paula Green,
  Vice President of Human Resources
• Bill Peck,
  Chief Technology Officer
• Erin Smith,
  Senior Vice President - Government affairs and Public policy
• Martin Kunz,
  Senior Vice President - Operation
• Patrick Weiss,
  Chief Operating Officer
• Tracey Mullen M.B.A.,
  Sr. VP of Operations
• Paula Green,
  Sr. VP of HR
• Dennis Cho,
  Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer
• Kevin B. Yankton,
  VP & Chief Accounting Officer
• Mark Daniels Esq.,
  Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec.
• Dr. Aaron K. Sato,
  Chief Scientific Officer & Chief Scientific Officer of BioPharma
• Siyuan Chen,
  Chief Technology Officer
• Adam Laponis,
  Chief Financial Officer
• Alpha Fund L.P. Ever,
  10% owner
• Fred B Craves,
  Director
• Venture Partners Viii, Llca...,
  
• Melissa A. Starovasnik,
  
• Dennis Cho,
  See Remarks
• Kevin Bruce Yankton,
  Chief Accounting Officer
• Robert F. Werner,
  Chief Accounting Officer